Quoin Price Earnings To Growth Ratio from 2010 to 2024

QNRX Stock  USD 0.59  0.03  4.84%   
Quoin Pharmaceuticals Price Earnings To Growth Ratio yearly trend continues to be fairly stable with very little volatility. Price Earnings To Growth Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Quoin Pharmaceuticals Price Earnings To Growth Ratio regression line of annual values had significance of  0.35 and arithmetic mean of  0.01. View All Fundamentals
 
Price Earnings To Growth Ratio  
First Reported
2010-12-31
Previous Quarter
0.00877505
Current Value
0.017
Quarterly Volatility
0.05404131
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Quoin Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Quoin Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 4 M, Total Revenue of 0.0 or Other Operating Expenses of 7 M, as well as many indicators such as Dividend Yield of 7.58, Ptb Ratio of 0.74 or Book Value Per Share of 5.97. Quoin financial statements analysis is a perfect complement when working with Quoin Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Quoin Pharmaceuticals Correlation against competitors.

Latest Quoin Pharmaceuticals' Price Earnings To Growth Ratio Growth Pattern

Below is the plot of the Price Earnings To Growth Ratio of Quoin Pharmaceuticals Ltd over the last few years. It is Quoin Pharmaceuticals' Price Earnings To Growth Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Quoin Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Price Earnings To Growth Ratio10 Years Trend
Pretty Stable
   Price Earnings To Growth Ratio   
       Timeline  

Quoin Price Earnings To Growth Ratio Regression Statistics

Arithmetic Mean0.01
Coefficient Of Variation457.18
Mean Deviation0.03
Median(0)
Standard Deviation0.05
Sample Variance0
Range0.2678
R-Value0.26
Mean Square Error0
R-Squared0.07
Significance0.35
Slope0
Total Sum of Squares0.04

Quoin Price Earnings To Growth Ratio History

2024 0.017
2023 0.008775
2022 0.007987
2021 -0.003182
2020 0.18
2019 0.0285
2018 0.0293

About Quoin Pharmaceuticals Financial Statements

Quoin Pharmaceuticals investors use historical fundamental indicators, such as Quoin Pharmaceuticals' Price Earnings To Growth Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Quoin Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Earnings To Growth Ratio 0.01  0.02 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Quoin Stock Analysis

When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.